JQ1(+) has been identified to be a promising cancer therapeutic, having been shown to prevent BRD4, a BET family protein, from interacting with and recruiting Myc, a transcription factor involved in cell proliferation that has been found to be constitutively active in several cancers, such as acute myeloid leukemia and multiple myeloma (42, 43). This evidence concerns the gene DNER and plasma cell myeloma.